Clinical Trial Update: A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial of MM120 for Generalized Anxiety Disorder is currently recruiting, sponsored by Definium Therapeutics US, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• MM120

Snippet

Sponsor: Definium Therapeutics US, Inc. | Conditions: Generalized Anxiety Disorder | Phase 3 | Status: RECRUITING